Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2015 (2015), Article ID 596164, 9 pages
http://dx.doi.org/10.1155/2015/596164
Review Article

Haemophilia A: Pharmacoeconomic Review of Prophylaxis Treatment versus On-Demand

1Department of Public Health and Infectious Diseases, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy
2Institute of Hygiene, Catholic University of the Sacred Heart, Largo Agostino Gemelli 8, 00168 Rome, Italy

Received 8 July 2014; Accepted 6 November 2014

Academic Editor: Angelos E. Hatzakis

Copyright © 2015 Brigid Unim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. Abbonizio, A. Giampaolo, C. Chelucci, R. Arcieri, and H. J. Hassan, “Associazione Italiana Centri Emofilia (AICE). Registro Nazionale Coagulopatie Congenite,” Tech. Rep. Rapporti ISTISAN 14/12, Istituto Superiore di Sanità, Roma, Italy, 2012. View at Google Scholar
  2. W. Schramm, S. Royal, B. Kroner et al., “Clinical outcomes and resource utilization associated with haemophilia care in Europe,” Haemophilia, vol. 8, no. 1, pp. 33–43, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. M. N. Di Minno, G. Di Minno, M. Di Capua, A. M. Cerbone, and A. Coppola, “Cost of care of haemophilia with inhibitors,” Haemophilia, vol. 16, no. 1, pp. e190–e201, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. M. M. Ullman and W. K. Hoots, “Assessing the costs for clinical care of patients with high-responding factor VIII and IX inhibitors,” Haemophilia, vol. 12, no. 6, pp. 74–80, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. C. Negrini, F. Daniele, M. E. Mancuso, G. F. Rivolta, and A. Tagliaferri, “Implicazioni economiche del trattamento dei pazienti emofilici con inibitori: una revisione sistematica della letteratura,” PharmacoEconomics-Italian Research Articles, vol. 8, no. 1, pp. 33–44, 2006. View at Google Scholar
  6. B. T. Colvin, J. Astermark, K. Fischer et al., “European principles of haemophilia care,” Haemophilia, vol. 14, no. 2, pp. 361–374, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. A. Tagliaferri, M. Franchini, A. Coppola et al., “Effects of secondary prophylaxis started in adolescent and adult haemophiliacs,” Haemophilia, vol. 14, no. 5, pp. 945–951, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. M. J. Manco-Johnson, T. C. Abshire, A. D. Shapiro et al., “Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia,” The New England Journal of Medicine, vol. 357, no. 6, pp. 535–544, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. M. F. Drummond, M. J. Sculpher, G. Torrance, J. O'Brien, and G. L. Stoddart, Methods for the Economic Evaluation of Health Care Programmes, Oxford University Press, New York, NY, USA, 3rd edition, 2005.
  10. J. P. T. Higgins and S. Green, Eds., Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0, The Cochrane Collaboration, 2011, http://handbook.cochrane.org/.
  11. M. F. Drummond and T. O. Jefferson, “Guidelines for authors and peer reviewers of economic submissions to the BMJ,” British Medical Journal, vol. 313, no. 7052, pp. 275–283, 1996. View at Publisher · View at Google Scholar · View at Scopus
  12. G. La Torre, N. Nicolotti, C. de Waure, and W. Ricciardi, “Development of a weighted scale to assess the quality of cost-effectiveness studies and an application to the economic evaluations of tetravalent HPV vaccine,” Journal of Public Health, vol. 19, no. 2, pp. 103–111, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Liberati, D. G. Altman, J. Tetzlaff et al., “The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration,” Italian Journal of Public Health, vol. 6, no. 4, pp. 354–391, 2009. View at Google Scholar · View at Scopus
  14. A. H. Miners, C. A. Sabin, K. H. Tolley, and C. A. Lee, “Cost-utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophilia,” PharmacoEconomics, vol. 20, no. 11, pp. 759–774, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. A. H. Miners, “Revisiting the cost-effectiveness of primary prophylaxis with clotting factor for the treatment of severe haemophilia A,” Haemophilia, vol. 15, no. 4, pp. 881–887, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. N. Risebrough, P. Oh, V. Blanchette, J. Curtin, J. Hitzler, and B. M. Feldman, “Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A,” Haemophilia, vol. 14, no. 4, pp. 743–752, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. B. Lippert, K. Berger, E. Berntorp et al., “Cost effectiveness of haemophilia treatment: a cross-national assessment,” Blood Coagulation & Fibrinolysis, vol. 16, no. 7, pp. 477–485, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. G. L. Colombo, S. di Matteo, M. Elisa Mancuso, and E. Santagostino, “Cost-utility analysis of prophylaxis versus treatment on demand in severe hemophilia A,” ClinicoEconomics and Outcomes Research, vol. 3, no. 1, pp. 55–61, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. S. Capri and W. Ricciardi, “Advate nel trattamento dellemofilia A—analisi costo-efficacia della terapia on-demand vs. profilassi basata sullemivita del prodotto,” The Italian Journal of Public Health, vol. 8, no. 2, pp. S61–S67, 2011. View at Google Scholar
  20. A. H. Miners, C. A. Sabin, C. H. Tolley, C. Jenkinson, P. Kind, and C. A. Lee, “Assessing health-related quality-of-life in individuals with haemophilia,” Haemophilia, vol. 5, no. 6, pp. 378–385, 1999. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Farrugia, J. Cassar, M. C. Kimber et al., “Treatment for life for severe haemophilia A: a cost-utility model for prophylaxis versus on-demand treatment,” Haemophilia, vol. 19, no. 4, pp. e228–e238, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. K. Kurnik, C. Bidlingmaier, W. Engl, H. Chehadeh, B. Reipert, and G. Auerswald, “New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development,” Haemophilia, vol. 16, no. 2, pp. 256–262, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. A. Srivastava, A. K. Brewer, E. P. Mauser-Bunschoten et al., “Guidelines for the management of hemophilia,” Haemophilia, vol. 19, no. 1, pp. e1–e47, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. A. Coppola, A. Tagliaferri, M. Di Capua, and M. Franchini, “Prophylaxis in children with hemophilia: evidence-based achievements, old and new challenges,” Seminars in Thrombosis and Hemostasis, vol. 38, no. 1, pp. 79–94, 2012. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. M. Richards, M. Williams, E. Chalmers et al., “A United Kingdom haemophilia centre doctors' organization guideline approved by the British committee for standards in haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A,” British Journal of Haematology, vol. 149, no. 4, pp. 498–507, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. A. H. Miners, “Economic evaluations of prophylaxis with clotting factor for people with severe haemophilia: why do the results vary so much?” Haemophilia, vol. 19, no. 2, pp. 174–180, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus